Optimization of Stability-Indicating HPLC Method for Analyzing Process Related Impurities of Penfluridol and Structural Elucidation of Stress Degradation Products by LCMS/MSucidation of Stress Degradation Products by LCMS/MS

Jump To References Section

Authors

  • Beram Adilakshmi
     Department of Engineering Chemistry, College of Engineering, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur - 522302, Andhra Pradesh ,IN
  • V. K. Rohini
     Department of Engineering Chemistry, College of Engineering, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur - 522302, Andhra Pradesh ,IN
  • T. Eswarlal
     Department of Engineering Mathematics, College of Engineering, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur - 522302, Andhra Pradesh ,IN
  • Ch. Lakshmi Prasanna
     Department of Engineering Chemistry, Sagi Rama Krishnam Raju Engineering College, Bhimavaram - 534204, Andhra Pradesh ,IN
  • Venkateswara Rao Anna
     Department of Engineering Chemistry, College of Engineering, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur - 522302, Andhra Pradesh ,IN

DOI:

https://doi.org/10.18311/ti/2023/v30i4/34033

Keywords:

Characterization of Degradation Compounds, HPLC Method Development, Impurity Analysis, Penfluridol, Stress Studies

Abstract

This study focused on the development of a simple and sensitive HPLC method for resolution and quantification of process-related impurities of penfluridol and further assessment of forced degradation behavior of penfluridol. The chromatographic separation was achieved on XTerra™ C18 (250×4.6 mm, 5.0μm) column and UV detection at 245nm. The mobile phase comprises of methanol and tetrahydrofuran in 55:45 (v/v) as solvent A and acetonitrile and tetrahydrofuran in 80:20 (v/v) as solvent B. The 60:40 (v/v) composition of solvent A and B were pumped isocratically at 1.0mL/min. In the proposed conditions, the retention time identified as 5.29 min for penfluridol, 4.51 min, 9.95 min and 7.64 min respectively for impurity 1, 2 and 3 with acceptable system suitability. The method produces sensitive detection limit of 0.008μg/mL for impurity 1, 2 and 0.004 μg/mL for impurity 3 with calibration range of 25-150 μg/mL for penfluridol and 0.025-0.150 μg/mL for impurities. The drug was exposed to different stressed conditions (acid, base, peroxide, thermal and UV light) according to ICH Q1A (R2) guidelines. The Degradation Products (DPs) formed during the stress study was characterized by LCMS/MS in ESI positive mode and the possible structures of five DPs with possible degradation pathways were proposed. The outcomes of other validation studies were likewise satisfactory and proven adequate for regular analysis of penfluridol and its process-related impurities in bulk drug and pharmaceutical dosage forms and can also applicable for evaluation of stress degradation mechanism of penfluridol.

Downloads

Download data is not yet available.

Downloads

Published

2023-11-06

How to Cite

Adilakshmi, B., Rohini, V. K., Eswarlal, T., Prasanna, C. L., & Anna, V. R. (2023). Optimization of Stability-Indicating HPLC Method for Analyzing Process Related Impurities of Penfluridol and Structural Elucidation of Stress Degradation Products by LCMS/MSucidation of Stress Degradation Products by LCMS/MS. Toxicology International, 30(4), 475–487. https://doi.org/10.18311/ti/2023/v30i4/34033

Issue

Volume 30, Issue 4, October-December 2023

Section

Articles

License

Copyright (c) 2023 Beram Adilakshmi, V. K. Rohini, T. Eswarlal, Ch. Lakshmi Prasanna, Venkateswara Rao Anna

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC
Received 2023-06-10
Accepted 2023-09-03
Published 2023-11-06

 

References

Holm R, David PE. Analytical advances in pharmaceutical impurity profiling. Eur J Pharm Sci. 2016; 87:118-35. https://doi.org/10.1016/j.ejps.2015.12.007 DOI: https://doi.org/10.1016/j.ejps.2015.12.007

Paskiet D, Jenke D, Ball D, Houston C, Norwood DL, Markovic I. The Product Quality Research Institute (PQRI) leachables and extractables working group initiatives for Parenteral and Ophthalmic Drug Product (PODP), PDA. J Pharm Sci Technol. 2013; 67(5):430-47. https://doi. org/10.5731/pdajpst.2013.00936 DOI: https://doi.org/10.5731/pdajpst.2013.00936

International Conference on Harmonization B. Q3B (R2): Impurities in New Drug Products. Guidel: ICH Harmon. Tripart; 2006. p. 12. https://doi.org/10.1017/ CBO9781107415324.004

Olsen BA, Sreedhara A, Baertschi SW. Impurity investigations by phases of drug and product development. TrAC Trends Anal Chem. 2017; 101:17-23. https://doi. org/10.1016/j.trac.2017.10.025 DOI: https://doi.org/10.1016/j.trac.2017.10.025

Mark HK, David E, Andrew T, Mark DM, Alan PM, Steven WB. Strategies to address mutagenic impurities derived from degradation in drug substances and drug products. Org Process Res Dev. 2015; 19(11):1447-57. https://doi. org/10.1021/acs.oprd.5b00091 DOI: https://doi.org/10.1021/acs.oprd.5b00091

Wei Y, Wu Y, Zhu T, Li Z, Zhang Y. Identification of UV-absorbing extractables from rubber closures used in containers of injectable powder and safety assessment of leachables in the drug. J Pharm Biomed Anal. 2017; 138:256-66. https://doi.org/10.1016/j.jpba.2017.02.023 DOI: https://doi.org/10.1016/j.jpba.2017.02.023

Jacobson-Kram D, McGovern T. Toxicological overview of impurities in pharmaceutical products. Adv Drug Deliv Rev. 2007; 59(1):38-42. https://doi.org/10.1016/j. addr.2006.10.007 DOI: https://doi.org/10.1016/j.addr.2006.10.007

Van Praag HM, Schut T, Dols L, van Schilfgaarden R. Controlled trial of penfluridol in acute psychosis. Br Med J. 1971; 18(4):710-3. https://doi.org/10.1136/bmj.4.5789.710 DOI: https://doi.org/10.1136/bmj.4.5789.710

Tuan NM, Lee CH. Penfluridol as a candidate of drug repurposing for anticancer agent. Molecules. 2019; 24(20):3659. https://doi.org/10.3390/molecules24203659 DOI: https://doi.org/10.3390/molecules24203659

Zoe Clarke, Penfluridol, editor(s): Enna SJ, Bylund DB. xPharm: The comprehensive pharmacology reference. Elsevier. 2007; 1-4. https://doi.org/10.1016/B978- 008055232-3.62384-0 DOI: https://doi.org/10.1016/B978-008055232-3.62384-0

Walia A, Rajput M, Lahoti N, Bhosale V, Khan A, Yadav R, Patil S. Analysis of anti-psychotic drug penfluridol in human plasma by HPLC and MS/MS. Trends Drug Deliv. 2022; 9(2):36-45.

Garay GL, Forfar-Bares I, Pehourcq F, Jarry C. Simultaneous determination of four antipsychotic drugs in plasma by high-performance liquid chromatography: Application to management of acute intoxications. J Chromatogr B. 2003; 795(2):257-64. https://doi.org/10.1016/S1570- 0232(03)00576-2 DOI: https://doi.org/10.1016/S1570-0232(03)00576-2

Weinmann W, Muller C, Vogt S, Frei A. LC-MS-MS analysis of the neuroleptics clozapine, flupentixol, haloperidol, penfluridol, thioridazine, and zuclopenthixol in hair obtained from psychiatric patients. J Anal Toxicol. 2002; 26(5):303-7. https://doi.org/10.1093/jat/26.5.303 DOI: https://doi.org/10.1093/jat/26.5.303

Sindelar K, Rajsner M, Cervena I, Valenta V, Jílek JO, Kakac K, Holubek J, Svatek E, Miksik F, Protiva M. Neurotropic and psychotropic agents. LXVII. 1-[4,4-Bis(4-fluorophenyl) butyl]-4-hydroxy-4-(3-trifluoromethyl-4-chlorophenyl) piperidine and related compounds: New synthetic approaches. Collect Czech Chem Commun. 1973; 38(12):3879-901. https://doi.org/10.1135/cccc19733879 DOI: https://doi.org/10.1135/cccc19733879

Miroslav R, Antonin D, Miroslav P. Esters of 1-[4,4-bis(4-fluorophenyl)butyl]-4-(4-chloro-3- trifluoromethylphenyl)-4-piperidinol. Collection of Czechoslovak Chemical Communications. 1981; 46(6):1530-3. https://doi.org/10.1135/cccc19811530 DOI: https://doi.org/10.1135/cccc19811530

Bikshal BK, Useni RM, Venkateswara RA, Maheshwara RL. Intended high-performance liquid chromatography procedure for the quantification of norfloxacin and its potential impurities in active pharmaceutical ingredient and tablet dosage forms. Thai J Pharm Sci. 2018; 42(1): 27-36.

Mallu UR, Anna VR, Kasimala BB. Rapid stability indicating HPLC method for the analysis of leflunomide and its related impurities in bulk drug and formulations. 2006. Turk J Pharm Sci. 2019; 16:457-65. https://doi.org/10.4274/ tjps.galenos.2018.34635 DOI: https://doi.org/10.4274/tjps.galenos.2018.34635

Kasimala BB, Anna VR, Mallu UR. Stability-indicating reversed-phase HPLC method for the separation and estimation of related impurities of cilnidipine in pharmaceutical formulations. Indian Drugs. 2019; 55(12): 41-9. https://doi.org/10.53879/id.55.12.11185 DOI: https://doi.org/10.53879/id.55.12.11185

Sri Girija K, Kasimala BB, Anna VR. A new high-performance liquid chromatography method for the separation and simultaneous quantification of eptifibatide and its impurities in pharmaceutical injection formulation. Int J App Pharm. 2021; 13(2):165-72. https://doi.org/10.22159/ijap.2021v13i2.39895 DOI: https://doi.org/10.22159/ijap.2021v13i2.39895

Varma RB, Rao BS. Gas chromatography-head spaceflame ionization sensor-based assessment of four residuary solvents in rivaroxaban bulk medication. Research Journal of Pharmacy and Technology. 2022; 15(11):5158-63. https:// doi.org/10.52711/0974-360X.2022.00868 DOI: https://doi.org/10.52711/0974-360X.2022.00868

Varma Rajesh BH, Sreenivasa Rao B. Gas Chromatographyhead space-mass spectrometry sensor based quality control of dobutamine hydrochloride bulk material for a mutagenic impurity, 2-bromopropane. Research Journal of Chemistry and Environment. 2023; 27(2):54-61. https:// doi.org/10.25303/2702rjce054061 DOI: https://doi.org/10.25303/2702rjce054061

Bhupatiraju RV, Rao BS, Kapavarapu MVNR, Reddy MV. A novel Rivaroxaban degradation impurity detection by RP-HPLC extraction by preparative chromatography, and characterization by LC-MS, NMR and FT-IR: Analysis of novel impurity in batch samples and tablets of Rivaroxaban. Rasayan Journal of Chemistry. 2022; 15(4):2373-81. https:// doi.org/10.31788/RJC.2022.1547008 DOI: https://doi.org/10.31788/RJC.2022.1547008

Bhupatirajua RV, Battulaa SR, Kapavarapu MVNR, Mandapati VR. Assessment of gas chromatography methodology approach for the trace evaluation of carcinogenic impurity, methyl chloride, in trimetazidine dihydrochloride. Annales Pharmaceutiques Francaises. 2023; 81:64-73. https://doi. org/10.1016/j.pharma.2022.06.012 DOI: https://doi.org/10.1016/j.pharma.2022.06.012

ICH Validation of Analytical Procedures: Text and Methodology Q2(R1); 1994. p. 1-13.

ICH guideline, Impurities in New Drug Substances, Q3A (R2), IFPMA, Geneva, Switzerland; 2006.